Company Overview and News

 
William Lamb Appointed as Executive Chairman of the Board

2018-09-24 globenewswire
VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Riley Resources Corp. (TSXV: RLY) (“Riley” or, the “Company”), is pleased to announce the appointment of William Lamb as Executive Chairman of the Board of Directors.
LUC LUCRF

93
CANADA STOCKS-TSX gains as oil boost helps energy stocks

2018-08-21 reuters - 1
(Reuters) - Canada’s main stock index rose on Tuesday as a rally in oil prices pushed energy shares higher.
ECN ACBFF MEG ECA TXG CGC SU LUC ECA RNX RNX.WT TWMJF ACB LUCRF RNKLF APH CNQ WEED FQVLF MEGEF APHQF FQM TORXF SU

 
Sarine Technologies collaborates with Lucara Diamond on blockchain-powered platform to sell diamonds

2018-08-21 theedgemarkets
SINGAPORE (Aug 20): Sarine Technologies has entered into an agreement with Clara Diamond Solutions, a subsidiary of Vancouver-based diamond mining producer Lucara Diamond.
LUC LUCRF

 
Lucara Diamond Corp. 2018 Q2 - Results - Earnings Call Slides

2018-08-09 seekingalpha
The following slide deck was published by Lucara Diamond Corp. in conjunction with their 2018 Q2 earnings call.
LUC LUCRF

 
More Boardroom Diversity Means Less in C-Suite, Lucara CEO Says - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUC LUCRF

177
CANADA STOCKS - TSX rises 0.42 pct as energy climbs

2018-06-18 reuters
NEW YORK, June 18 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 69.21 points, or 0.42 percent, to 16,383.63. * The biggest contributor to the TSX gain was TransCanada , while the top sector contributor was energy. * Leading the index were Canada Goose Holdings Inc, up 9.8 percent, Bombardier Inc, up 6.4 percent, and Lucara Diamond Corp , higher by 6.1 percent. * Lagging shares were Baytex Energy Corp, down 12.
LUC GOOS LUCRF BDRPF VRX RRENF BTE RRX

6
Orca Gold Inc. Announces Annual General Meeting Results and New Chief Financial Officer

2018-06-01 globenewswire
VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Orca Gold Inc. (TSXV:ORG) (“Orca” or the “Company”) is pleased to announce that the nominees set forth in the Company’s management information circular dated April 26, 2018, L. Simon Jackson, Richard Clark, Hugh Stuart, Alexander Davidson, Robert Chase, David Field and Derek White were elected as directors of the Company at the Annual General Meeting held on May 30, 2018 (the “Meeting”).
LUC LUCRF AAUKF AAL CANWF ORG NGLOY

 
Lucara Announces Declaration of Quarterly Dividend

2018-05-09 globenewswire
VANCOUVER, BRITISH COLUMBIA, May 08, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC)(BOTSWANA:LUC)(NASDAQ OMX Stockholm:LUC) is pleased to announce that the Board of Directors has declared the second 2018 quarterly dividend of CDN 2.5 cents per share to be payable Thursday, June 21, 2018 to the shareholders of record at the close of business on Friday, June 8, 2018.
LUC LUCRF

 
Lucara Announces First Quarter 2018 Results

2018-05-08 globenewswire
Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC)(BOTSWANA:LUC)(NASDAQ OMX Stockholm:LUC) is pleased to announce results for the three months ended March 31, 2018.
LUC LUCRF

 
Lucara Announces Appointment of Managing Director, Boteti Botswana

2018-05-01 globenewswire
(LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) is pleased to announce the promotion of Naseem Lahri, BCOM, FCCA to Managing Director of Boteti Mining (Pty) Ltd, Lucara’s 100% owned subsidiary in Botswana, effective immediately.
LUC LUCRF

 
LUCARA 2018 FIRST QUARTER RESULTS TO BE RELEASED TUESDAY, MAY 8, 2018

2018-04-19 globenewswire
VANCOUVER, BRITISH COLUMBIA, April 19, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) announces that it will be publishing its 2018 First Quarter results on Tuesday, May 8, 2018, after the market close in North America.
LUC LUCRF

 
Lucara 2018 First Quarter Results to Be Released Tuesday, May 8, 2018

2018-04-19 globenewswire
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) announces that it will be publishing its 2018 First Quarter results on Tuesday, May 8, 2018, after the market close in North America.
LUC LUCRF

 
Lucara Unearths Another Massive Diamond From Botswana Mine - Bloomberg

2018-04-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUC LUCRF

 
Lucara Annual General Meeting to Be Held May 10, 2018

2018-04-10 globenewswire
VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) announces that its Annual General Meeting of Shareholders will be held at Suite 2600, Pacific Boardroom, 595 Burrard Street, Vancouver, British Columbia, V7X 1L3 on Thursday, May 10, 2018, at 10:00 a.m. (Pacific Daylight Time), for the following purposes:
LUC LUCRF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 54928Q108